Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATEC
SellSinkerAlphatec Holdings, Inc. · Healthcare · United States · $1.5B · Avg Vol: $18M/d
COMPANY DESCRIPTION
Alphatec Holdings, Inc. is a medical technology company dedicated to designing, developing, and commercializing innovative surgical solutions for complex spinal disorders. The company's competitive moat is formed by its proprietary procedural solutions and integrated product portfolio, which focuses on improving clinical outcomes through surgeon education and advanced techniques. By emphasizing a comprehensive approach to spine care, Alphatec aims to be a leader in the specialized spinal surgery market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350.9M | 482.3M | 611.6M | 764.2M | 29.6% | 815.1M | 882.1M | 1.0B | 15.3% |
| EPS | -1.47 | -1.54 | -1.13 | -0.96 | — | -0.71 | — | — | — |
| Shares | 106.6M | 139.2M | 144.1M | 148.4M | +39.2% | 154.5M | — | — | — |
| Debt | 395.9M | 541.7M | 609.9M | 596.1M | 14.6% | 604.0M | — | — | — |
| Equity | -34.7M | 78.1M | -14.2M | 12.4M | -60.1% | — | — | — | — |
| Op CF | -75.1M | -78.5M | -44.7M | 45.2M | — | 56.5M | — | — | — |
| Inv CF | -58.3M | -142.0M | -93.1M | -53.4M | — | — | — | — | — |
| Fin CF | 31.2M | 356.9M | 56.2M | 30.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATEC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATEC | Alphatec Holdings, Inc.(you) | $1.5B | 27 | Sell |
| TNDM | Tandem Diabetes Care, Inc. | $1.5B | 31 | Sell |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 28 | Sell |
| QDEL | QuidelOrtho Corporation | $1.0B | 29 | Sell |
| CBLL | CeriBell, Inc. | $911M | 27 | Sell |
| BBNX | Beta Bionics, Inc. | $887M | 27 | Sell |
| AORT | Artivion, Inc. | $1.3B | 36 | Hold |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | 23 | Sell |
| ALMR | Alamar Biosciences, Inc. | $2.1B | 20 | Sell |
| TMDX | TransMedics Group, Inc. | $3.1B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%